Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt
Open access

Lecanemab in symptomatic PSEN1 p.Met233Val early‐onset Alzheimer's disease: Neuroimaging safety, regional amyloid‐PET dynamics, and longitudinal plasma biomarkers

Min-Young Noh Wonjae Sung Hyunkee Kim Bugyeong Son Young-Eun Kim Yun Y. Choi David M. Holtzman Seung Hyun Kim
Jul 2026 · Alzheimer's & Dementia · Vol 18 · 0 citations · 20 references
Medicine

Abstract

The presenilin 1 (PSEN1) p.Met233Val variant is a Dominantly Inherited Alzheimer Network–Trials Unit (DIAN‐TU)–eligible autosomal‐dominant Alzheimer's disease (ADAD) variant for which lecanemab response data are unavailable.

DOI PubMed Semantic Scholar
Read PDF

Similar papers

Open access Sep 2026

Cerebrospinal Fluid p75 Neurotrophin Receptor Ectodomain Levels Across Clinically Diagnosed Alzheimer's Disease, Late‐Life Depression, and Healthy Aging: A Preliminary Cross‐Sectional Study

The p75 neurotrophin receptor ectodomain (p75NTR‐ECD) has been implicated in amyloid‐β‐related neurotoxicity, but cerebrospinal fluid (CSF) levels in late‐life depression (LLD) remain uncertain. We compared clinically diagnosed Alzheimer's disease (AD), LLD, and healthy controls (HC) and reassessed exploratory symptom...

W. Omori, N. Kajitani, M. Okada-Tsuchioka et al. · 0 citations
Open access Sep 2026

TMEM106B is a selective modulator of TDP‐43 pathology in Alzheimer's disease

Co‐pathologies – including Lewy body, vascular, and TDP‐43 lesions – are common in Alzheimer's disease (AD), contributing to its clinical and pathological heterogeneity. Genetic risk factors may drive mixed pathology presentation, but their influence on the development of specific co‐pathologies remains unclear.

Madison M. Reeves, Anna Calliari, Tiffany W. Todd et al. · 0 citations
Open access Sep 2026

Post mortem MRI of cholinergic white matter pathways across neurodegenerative diseases

Cholinergic white matter pathway degeneration is central in Alzheimer's disease and Lewy body disease and can be assessed in vivo using magnetic resonance imaging proxies, but neuropathological validation is limited.

F. López-González, M. Němý, C. Jerele et al. · 0 citations
Open access Sep 2026

Changes in serum β‐synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome

There is a need for early, objective markers of Alzheimer's disease (AD)‐related synapse dysfunction in adults with Down syndrome (DS). The presynaptic protein β‐synuclein is elevated in the blood of adults with DS. This study evaluates the positioning of these changes relative to changes in pathophysiological blood bi...

Alba Cervantes González, A. Morcillo-Nieto, Sara Serrano et al. · 0 citations
Review Open access Sep 2026

CSF Tau and Amyloid Biomarkers in Cognitive Impairment Across the ALS–FTD Spectrum: A Systematic Narrative Review and Evidence Map

Cognitive impairment is an important non‐motor manifestation of amyotrophic lateral sclerosis (ALS), particularly across the ALS–frontotemporal dementia (ALS–FTD) spectrum. Cerebrospinal fluid (CSF) tau and amyloid biomarkers may reflect nonspecific neurodegenerative injury, concomitant Alzheimer disease (AD) pathology...

Aasim Ali, Muhammad Arif, Usama Ashraf et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.